Kursinformationen (Nasdaq)
- Tagestief / Hoch-
- 52W-Tief / Hoch67,830-86,290
- Jahrestief / Hoch65,070-86,290
- Volumen Intraday
Wichtigste Eigenschaften
Werbung
Schnellsuche von
Termine von Incyte Corp.
- Mai2Incyte Corp.Q1 2023 Earnings Release
- Aug1Incyte Corp.Q2 2023 Earnings Release
- Okt31Incyte Corp.Q3 2023 Earnings Release
Beschreibung
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Pivot-Points (Nasdaq)
NameWert
- Pivot-HBOP - R372,113 $
- Pivot-Resist - R271,667 $
- Pivot-High - R171,403 $
- Pivotpunkt70,957 $
- Pivot-Low - S170,693 $
- Pivot-Support - S270,247 $
- Pivot-LBOP - S369,983 $
Passender Service zu Incyte Corp.
Webinar zu Incyte Corp.
Incyte Corp. Kurse
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit |
|---|---|---|---|---|---|
Wichtige Bewertungskennzahlen
Keine Kennzahlen vorhanden
Passende Produkte
Wertentwicklung (Nasdaq)
-0,01 %
Intraday
-1,56 %
1 Woche
-7,99 %
1 Monat
-11,44 %
Seit Jahresbeginn
-10,71 %
1 Jahr
-1,43 %
3 Jahre
-14,63 %
5 Jahre
203,87 %
10 Jahre
Peer Group
Novo-Nordisk AS 321,37 Mrd. €
Regeneron Pharmaceuticals Inc. 90,41 Mrd. $
Vertex Pharmaceuticals Inc. 80,53 Mrd. $
Moderna Inc. 56,66 Mrd. $
Seagen Inc. 37,99 Mrd. $
Alnylam Pharmaceuticals Inc 23,40 Mrd. $
argenx SE 18,76 Mrd. €
Biomarin Pharmaceutical Inc. 17,06 Mrd. $
UCB S.A. 15,24 Mrd. €
ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001 16,43 Mrd. $
